Premium
Clinical profile, morbidity, and outcome of adult‐onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia
Author(s) -
Choon Siew Eng,
Lai Nai Ming,
Mohammad Norshaleyna A,
Nanu Nalini M,
Tey Kwee Eng,
Chew Shang Fern
Publication year - 2014
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/ijd.12070
Subject(s) - medicine , generalized pustular psoriasis , psoriasis , leukocytosis , acitretin , diabetes mellitus , methotrexate , adalimumab , family history , arthritis , dermatology , pediatrics , rheumatoid arthritis , endocrinology
Background Generalized pustular psoriasis ( GPP ) is a severe but rare variant of psoriasis. Our objective is to review the clinical profile, comorbidities, and outcome of patients with GPP . Materials and methods A retrospective note review of all patients with adult‐onset GPP . Results A total of 102 patients with adult‐onset GPP were diagnosed between 1989 and November 2011, with a female to male ratio of 2 : 1. The mean age at onset of GPP was 40.9 years (range: 21–81 years). Acute GPP was the most common variant seen (95 cases), followed by four localized variants of GPP and three with annular pustular psoriasis. Fever and painful skin were present in 89% of patients, arthritis in 34.7%, and leukocytosis in 78.4%. Common triggers were systemic steroids (45 cases), pregnancy (17 cases), and upper respiratory tract infections (16 cases). A positive family history of psoriasis and GPP was present in 29% and 11%, respectively. Comorbidities included obesity (42.9%), hypertension (25.7%), hyperlipidemia (25.7%), and diabetes mellitus (23.7%). The mean duration of admission and pustular flare for acute GPP was 10.3 days (range: 3–44 days) and 16 days (range: 7–60 days), respectively. Fifty‐four patients responded to systemic retinoid, 21 to methotrexate, eight to cyclosporine, and one to adalimumab, but recurrences were common. Conclusions Our study confirms the poor response of GPP to currently available anti‐psoriatic agents, with frequent flare‐ups. There is a need for a more effective targeted therapy for this condition.